• LAST PRICE
    1.0300
  • TODAY'S CHANGE (%)
    Trending Down-0.0300 (-2.8302%)
  • Bid / Lots
    1.0200/ 29
  • Ask / Lots
    1.0300/ 6
  • Open / Previous Close
    1.0200 / 1.0600
  • Day Range
    Low 1.0200
    High 1.0300
  • 52 Week Range
    Low 1.0100
    High 8.7000
  • Volume
    8,370
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 1.06
TimeVolumeSMMT
09:32 ET66681.02
09:36 ET3541.02
09:38 ET6001.03
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSMMT
Summit Therapeutics Inc
110.9M
-1.1x
---
United StatesORIC
Oric Pharmaceuticals Inc
110.9M
-1.7x
---
United StatesLPTX
Leap Therapeutics Inc
115.7M
-2.2x
---
United StatesSURF
Surface Oncology Inc
107.0M
-1.6x
---
United StatesTFFP
TFF Pharmaceuticals Inc
109.4M
-4.2x
---
United StatesAKUS
Akouos Inc
109.1M
-1.2x
---
As of 2022-05-18

Company Information

Summit Therapeutics Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing novel antibiotics for serious infectious diseases. Its lead CDI product candidate is ridinilazole is an orally administered small molecule antibiotic. The Company's preclinical candidates include SMT-738, from the DDS-04 series for development in the fight against multidrug-resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections. The Company is conducting a Phase III clinical program focused on the infectious disease C. difficile infection (CDI). The Company is also seeking to expand its product candidate portfolio through the development of a new mechanism, precision antibiotics using its proprietary Discuva Platform.

Contact Information

Headquarters
One Broadway, 14Th FloorCAMBRIDGE, MA, United States 02142
Phone
617-514-7149
Fax
302-655-5049

Executives

Executive Chairman of the Board
Robert Duggan
Chief Financial Officer
Michael Donaldson
Chief Operating Officer, Director
Mahkam Zanganeh
Chief Scientific Officer
David Powell
Director
Kenneth Clark

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$110.9M
Revenue (TTM)
$1.9M
Shares Outstanding
98.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.09
EPS
$-0.97
Book Value
$0.85
P/E Ratio
-1.1x
Price/Sales (TTM)
59.4
Price/Cash Flow (TTM)
---
Operating Margin
-4,896.68%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.